ADAMTS13 and thrombotic thrombocytopenic purpura: B. Lämmle is chairman of data monitoring committees of studies investigating recombinant ADAMTS13 for the treatment of congenital and acquired TTP (Takeda), chairman of a steering committee analyzing global impact of congenital TTP (Takeda), and chairman of the data monitoring committee of Mayari study (investigating caplacizumab for the treatment of autoimmune TTP without plasma exchange (Sanofi-Genzyme)).